Trial Profile
A Randomized, Double-Blind, Placebo-Controled, Multicenter Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects Following A Low-Calorie Diet Lead-In
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Pramlintide-metreleptin (Primary)
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amylin Pharmaceuticals; Bristol-Myers Squibb
- 06 Dec 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 04 Aug 2011 Status changed from suspended to discontinued.
- 17 Mar 2011 Status changed from active, no longer recruiting to suspended.